Drug Information

Drug General Information
Drug ID
D03YBJ
Former ID
DIB016585
Drug Name
DS-8895
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524936]
Target and Pathway
Target(s) Ephrin type-A receptor 2 Target Info [531635], [550589]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Axon guidance
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database EphrinA-EPHA pathway
Arf6 signaling events
Direct p53 effectors
EPHA forward signaling
Stabilization and expansion of the E-cadherin adherens junction
EPHA2 forward signaling
Reactome EPH-Ephrin signaling
EPHA-mediated growth cone collapse
EPH-ephrin mediated repulsion of cells
WikiPathways NRF2 pathway
References
Ref 524936ClinicalTrials.gov (NCT02252211) Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers. U.S. National Institutes of Health.
Ref 531635Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
Ref 550589Clinical pipeline report, company report or official report of Daiichi Sankyo.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.